Federal officials have extended the temporary rules allowing health providers to prescribe controlled substances for opioid addiction and ADHD over telehealth until the end of 2025. The extension comes after months of debate among policymakers and aims to address the urgent public health need for continued access to buprenorphine for opioid use disorder. While proponents of the extension are celebrating, some concerns remain about potential fraudulent and harmful prescribing practices. Telehealth companies and advocates support oversight to prevent such practices but worry about the impact on progress made in opioid addiction care. Congress is also considering legislation to extend telehealth services for Medicare enrollees for two more years.
Source link
Extension granted for addiction treatment and stimulants via telehealth
